European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen’s disease, basal cell carcinoma

Morton, C.A.; Szeimies, Rolf‐Markus; Sidoroff, A.; Braathen, Lasse R.

doi:10.1111/jdv.12031

Cited by 306 publications

(370 citation statements)

References 102 publications

(201 reference statements)

Supporting

Mentioning

327

Contrasting

Unclassified

Order By: Relevance

“…Although c‐PDT is a successful treatment for AK,5, 9, 24 the unpredictability of tolerance during treatment in some patients, extended treatment times, and costly instrumentation has limited its use. Daylight PDT is a simple and practical new treatment option for AK that allows large areas of actinic damage to be treated with reduced in‐clinic treatment times and little or no pain.…”

Section: Resultsmentioning

confidence: 99%

Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia

See¹,

Shumack

Murrell

et al. 2015

Aust J Dermatology

View full text Add to dashboard Cite

Australia has the highest prevalence of actinic keratoses (AK) worldwide. Because of the risk of transformation of AK to invasive squamous cell carcinomas, consensus guidelines recommend that AK are removed using appropriate therapies to prevent progression to invasive disease. Daylight photodynamic therapy (PDT) is emerging as an efficacious treatment for AK, particularly for patients who require treatment of large areas of chronic actinic damage that can be exposed easily to daylight. Daylight PDT with methyl aminolevulinate (MAL) cream is a simple treatment for AK, almost painless, well tolerated and convenient, requiring minimal time in the clinic. Randomised controlled studies from northern Europe and Australia support the use of daylight PDT as an effective therapy for grade I and II AK on the face and scalp. There is sufficient daylight to conduct daylight PDT in Australia at any time of the year and during most weather conditions. Hence, daylight PDT with MAL can be included as an effective and well‐tolerated new treatment option for the treatment of AK in Australia. These consensus recommendations provide guidelines for Australian clinicians on the use of daylight PDT in the treatment of diagnosed AK.

show abstract

Section: Resultsmentioning

confidence: 99%

Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia

See¹,

Shumack

Murrell

et al. 2015

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…Protoporphyrin IX (PpIX)-induced PDT (PpIX-PDT) is utilised as topical method of localised ablation of certain non-melanoma skin cancers and precancers [4]. 5-Aminolevulinic acid (ALA)-induced photodynamic therapy (ALA-PDT) was first introduced experimentally by…”

Section: Introductionmentioning

confidence: 99%

The importance of iron chelation and iron availability during PpIX-induced photodynamic therapy

Curnow

Pye

2015

Photonics &Amp; Lasers in Medicine

View full text Add to dashboard Cite

show abstract

“…PDT has been also used for treatment of Bowen's disease, or squamous cell carcinoma in situ and is recommended for both extensive involvement and poor healing sites [98]. The approved MAL-PDT dosing regimen for Europe consists of two treatments 7 days apart, repeated at 3 months, if needed [99].…”

Section: Squamous Cell Carcinomamentioning

confidence: 99%

Photodynamic Therapy and Skin Cancer

Papakonstantinou¹,

Löhr²,

Raap³

2018

Dermatologic Surgery and Procedures

View full text Add to dashboard Cite

Non-melanoma skin cancer (NMSC) is the most common type of cancer among white skin individuals worldwide with an increasing incidence over the last years. NMSC is mostly treated with surgical or non-invasive methods such as cryotherapy or topical chemotherapeutics. Over the last years, there has been a rapidly growing interest in the use of photodynamic therapy (PDT) which is a well-tolerated, safe and effective alternative treatment option. PDT involves a photosensitizer, a light source and tissue oxygen and is based on a photo-oxidation reaction in the target tissue which results to a selective destruction of the cancer cells. PDT has been approved for treatment of actinic keratosis, Bowen's disease and basal cell carcinoma in Europe. Off-label uses include treatment of invasive squamous cell carcinoma, cutaneous T-cell lymphoma, Kaposi's sarcoma, Paget's disease and prevention of recurrence of squamous cell carcinoma in organ-transplant recipients. Also combination of PDT with other treatment options such as cryotherapy, surgery and topical therapies has been reported with improved efficacy, tolerability and long-term results. Development of novel photosensitizers and light sources together with targeted delivery systems will increase specificity, efficiency and treatment field of PDT in the future. This chapter aims to give the reader an overview of the important applications of PDT, including indications, approved treatments, advantages and disadvantages of this method such as future trends.

show abstract

European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen’s disease, basal cell carcinoma

Cited by 306 publications

References 102 publications

Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia

Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia

The importance of iron chelation and iron availability during PpIX-induced photodynamic therapy

Photodynamic Therapy and Skin Cancer

Contact Info

Product

Resources

About